SEATTLE, Wash. and VANCOUVER, British Columbia, October 31, 2018 – – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline (cytisine) for smoking cessation, today announced that it will report its third quarter 2018 financial results on Wednesday, November 7, 2018. Company management will host…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, October 30, 2018 – – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced initiation of the Phase 2b ORCA-1 trial for smoking cessation. ORCA-1 is the first in Achieve’s ORCA (Ongoing Research of…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, October 1, 2018 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 1,789,258 shares…
/Read More
SEATTLE, Wash and VANCOUVER, British Columbia, Sept. 27, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced results of a clinical study evaluating the effect of food on the bioavailability of a new formulation for cytisine. The study…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, Sept. 26, 2018 – – Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that Rick Stewart, Chairman and Chief Executive Officer, will present at the Ladenburg Thalmann 2018 Healthcare Conference being held Tuesday,…
/Read More